Royalty Pharma Announces Agreement To Purchase Up To $1.5B Of PTC Therapeutics' Royalty On Evrysdi
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma has announced an agreement to purchase up to $1.5 billion of PTC Therapeutics' royalty on Evrysdi. The deal involves an upfront payment of $1.0 billion, with an option for PTC Therapeutics to sell the rest of the royalty for up to $500 million. Royalty Pharma also has the option to buy half of the remaining royalty for up to $250 million. The transaction is expected to enhance Royalty Pharma's long-term Adjusted Cash Receipts growth.
October 19, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The acquisition of PTC Therapeutics' royalty on Evrysdi by Royalty Pharma is expected to enhance its long-term Adjusted Cash Receipts growth. This could potentially lead to a positive impact on the company's stock.
The acquisition of royalties is a direct revenue source for Royalty Pharma. The deal, which involves a significant amount of $1.5 billion, is expected to enhance the company's long-term Adjusted Cash Receipts growth. This could potentially lead to increased profitability and a positive impact on the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100